AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KALA BIO, Inc. Director's Dealing 2021

Jun 29, 2021

35091_dirs_2021-06-29_39f99462-ca8f-4183-8283-e28aab16140c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2021-06-28

Reporting Person: Reumuth Mary (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-28	Common Stock	S	2452	$5.77	Disposed	145507	Direct

Footnotes

F1: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2: Includes 91,666 unvested RSUs.